» Articles » PMID: 22788812

The Leprosy Agents Mycobacterium Lepromatosis and Mycobacterium Leprae in Mexico

Overview
Journal Int J Dermatol
Specialty Dermatology
Date 2012 Jul 14
PMID 22788812
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mycobacterium leprae was the only known cause of leprosy until 2008, when a new species, named Mycobacterium lepromatosis, was found to cause diffuse lepromatous leprosy (DLL), a unique form of leprosy endemic in Mexico.

Methods: We sought to differentiate the leprosy agents among 120 Mexican patients with various clinical forms of leprosy and to compare their relative prevalences and disease features. Archived skin biopsy specimens from these patients were tested for both M. leprae and M. lepromatosis using polymerase chain reaction-based species-specific assays.

Results: Etiologic species were confirmed in 87 (72.5%) patients, of whom 55 were infected with M. lepromatosis, 18 with M. leprae, and 14 with both organisms. The endemic regions of each agent differed but overlapped. Patients with M. lepromatosis were younger and were distributed across more states; their clinical diagnoses included DLL (n = 13), lepromatous leprosy (LL) (n = 34), and eight other forms of leprosy. By contrast, the diagnoses of patients with M. leprae did not include DLL but did include LL (n = 15) and three other forms of leprosy. Thus, M. lepromatosis caused DLL specifically (P = 0.023). Patients with M. lepromatosis also showed more variable skin lesions; the extremities were the most common sites of biopsy in these patients. Finally, patients with dual infections manifested all clinical forms and accounted for 16.1% of all species-confirmed cases.

Conclusions: Mycobacterium lepromatosis is another cause of leprosy and is probably more prevalent than M. leprae in Mexico. It mainly causes LL and also specifically DLL. Dual infections caused by both species may occur in endemic areas.

Citing Articles

Bioinformatic, structural, and biochemical analysis leads to the discovery of novel isonitrilases and decodes their substrate selectivity.

Hostetler T, Chen T, Chang W RSC Chem Biol. 2025; .

PMID: 39944535 PMC: 11811631. DOI: 10.1039/d4cb00304g.


Iron and vitamin D intake on a diet are able to modify the in vitro immune response to Mycobacterium leprae.

Martins B, Perico J, Bertoluci D, Barbosa A, Rosa P, Nogueira M Mem Inst Oswaldo Cruz. 2024; 119:e230178.

PMID: 39166620 PMC: 11329276. DOI: 10.1590/0074-02760230178.


Unlocking Opportunities for and .

Shyam M, Kumar S, Singh V ACS Infect Dis. 2024; 10(2):251-269.

PMID: 38295025 PMC: 10862552. DOI: 10.1021/acsinfecdis.3c00371.


Effective amelioration of the Lucio phenomenon with adjuvant tofacitinib therapy in a patient with dual infection of and : a case report from India.

Patel N, Padhiyar J, Patel K, Patel J, Lakum M, Singh I Access Microbiol. 2023; 5(10).

PMID: 37970083 PMC: 10634479. DOI: 10.1099/acmi.0.000460.v3.


Leprosy among children in an area without primary health care coverage in Caratateua Island, Brazilian Amazon.

Costa I, Costa P, da Silva S, Gobbo A, do Carmo Pinto P, Spencer J Front Med (Lausanne). 2023; 10:1218388.

PMID: 37425318 PMC: 10323681. DOI: 10.3389/fmed.2023.1218388.


References
1.
Lopez Roa R, Morris M . Leprosy in Mexico. Nihon Hansenbyo Gakkai Zasshi. 2006; 75(1):51-8. DOI: 10.5025/hansen.75.51. View

2.
Costa I, Kawano L, Pereira C, Nogueira L . Lucio's phenomenon: a case report and review of the literature. Int J Dermatol. 2005; 44(7):566-71. DOI: 10.1111/j.1365-4632.2005.02566.x. View

3.
Monot M, Honore N, Garnier T, Araoz R, Coppee J, Lacroix C . On the origin of leprosy. Science. 2005; 308(5724):1040-2. DOI: 10.1126/science/1109759. View

4.
Rea T, Bevans L, Taylor C . The histopathology of the spleen from a patient with lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1980; 48(3):285-90. View

5.
Choon S, Tey K . Lucio's phenomenon: a report of three cases seen in Johor, Malaysia. Int J Dermatol. 2009; 48(9):984-8. DOI: 10.1111/j.1365-4632.2009.04078.x. View